Madrigal Pharmaceuticals, Inc.

DB:YDO1 Stock Report

Market Cap: €6.6b

Madrigal Pharmaceuticals Valuation

Is YDO1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of YDO1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: YDO1 (€308.5) is trading below our estimate of fair value (€1956.94)

Significantly Below Fair Value: YDO1 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for YDO1?

Key metric: As YDO1 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for YDO1. This is calculated by dividing YDO1's market cap by their current book value.
What is YDO1's PB Ratio?
PB Ratio9.2x
BookUS$777.16m
Market CapUS$6.92b

Price to Book Ratio vs Peers

How does YDO1's PB Ratio compare to its peers?

The above table shows the PB ratio for YDO1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.6x
BIO3 Biotest
2.1x82.7%€1.4b
FYB Formycon
1.4x31.5%€821.0m
KRYS Krystal Biotech
5.9x41.2%US$5.1b
2INV 2invest
1xn/a€62.7m
YDO1 Madrigal Pharmaceuticals
9.2x73.1%€6.9b

Price-To-Book vs Peers: YDO1 is expensive based on its Price-To-Book Ratio (9.2x) compared to the peer average (2.6x).

Price to Book Ratio vs Industry

How does YDO1's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
YDO1 9.2xIndustry Avg. 2.3xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: YDO1 is expensive based on its Price-To-Book Ratio (9.2x) compared to the European Biotechs industry average (2.3x).

Price to Book Ratio vs Fair Ratio

What is YDO1's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

YDO1 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio9.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate YDO1's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst YDO1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€308.50
€353.14
+14.5%
22.1%€502.86€147.06n/a15
Nov ’25€289.30
€337.81
+16.8%
23.8%€489.08€143.03n/a15
Oct ’25€187.95
€332.15
+76.7%
23.1%€468.18€137.43n/a15
Sep ’25€222.00
€332.15
+49.6%
23.1%€468.18€137.43n/a15
Aug ’25€256.80
€335.12
+30.5%
22.6%€465.07€137.60n/a15
Jul ’25€259.30
€339.18
+30.8%
22.6%€471.05€139.37n/a15
Jun ’25€216.20
€334.64
+54.8%
23.5%€466.29€137.96n/a14
May ’25€190.15
€351.51
+84.9%
23.0%€526.69€139.83n/a14
Apr ’25€245.60
€363.13
+47.9%
15.7%€520.03€248.51n/a13
Mar ’25€231.60
€294.30
+27.1%
18.0%€375.58€143.03n/a12
Feb ’25€202.90
€295.04
+45.4%
14.0%€351.94€187.46n/a12
Jan ’25€208.40
€289.63
+39.0%
17.9%€351.13€141.19n/a12
Dec ’24€194.90
€289.63
+48.6%
17.9%€351.13€141.19n/a12
Nov ’24€128.45
€300.11
+133.6%
21.3%€385.69€145.22€289.3012
Oct ’24€137.05
€304.54
+122.2%
17.9%€382.04€208.72€187.9512
Sep ’24€170.50
€305.32
+79.1%
15.8%€373.17€204.38€222.0011
Aug ’24€183.10
€310.25
+69.4%
15.0%€378.68€203.91€256.8011
Jul ’24€210.40
€310.25
+47.5%
15.0%€378.68€203.91€259.3011
Jun ’24€248.00
€306.53
+23.6%
17.7%€385.05€207.33€216.2012
May ’24€283.00
€289.62
+2.3%
18.3%€379.64€177.90€190.1512
Apr ’24€222.00
€295.22
+33.0%
17.2%€367.65€182.88€245.6012
Mar ’24€260.00
€295.22
+13.5%
17.2%€367.65€182.88€231.6012
Feb ’24€260.00
€284.67
+9.5%
18.4%€366.41€182.26€202.9012
Jan ’24€276.00
€273.41
-0.9%
16.6%€353.85€183.06€208.4012
Dec ’23€69.00
€156.44
+126.7%
23.6%€208.14€76.90€194.9012
Nov ’23€74.50
€152.31
+104.4%
23.5%€202.86€74.95€128.4512

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Regeneron Pharmaceuticals

US$80.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$705.00

7D

-7.1%

1Y

-3.8%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.60

7D

-6.2%

1Y

90.0%

Collegium Pharmaceutical

US$967.5m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$28.60

7D

0.7%

1Y

20.2%